The HPS5 Knockout NCI-H1975 Polyclonal Cells product comprises a population of human NCI-H1975 lung adenocarcinoma cells that have been subjected to CRISPR/Cas9-mediated disruption of the HPS5 gene. The resulting polyclonal knockout cells harbor a heterogeneous ensemble of loss-of-function alleles across the culture, providing a robust tool for studying HPS5 function without clonal selection. This format preserves the cellular complexity and phenotypic diversity inherent to a polyclonal population, enabling the study of gene function in a context that more closely mimics variable knockout efficiencies encountered in complex biological systems.
The parental NCI-H1975 cell line is derived from the pleural effusion of a 65-year-old female never-smoker with non-small cell lung cancer and carries activating EGFR L858R and T790M mutations. These cells represent a well-established model of EGFR tyrosine kinase inhibitor (TKI)-resistant lung adenocarcinoma, making them relevant for dissecting mechanisms of oncogenic signaling, drug resistance, and tumor progression. The epithelial origin and genomic background of NCI-H1975 cells provide a defined genetic landscape for evaluating gene function in the context of endogenously mutated EGFR-driven malignancy.
HPS5 encodes an essential subunit of the biogenesis of lysosome-related organelles complex 2 (BLOC-2), a multi-protein assembly that also includes HPS3 and HPS6. The BLOC-2 complex functions downstream of the MITF transcription factor and coordinates the maturation and trafficking of lysosome-related organelles such as melanosomes, platelet dense granules, and lytic granules. HPS5-mediated complex formation facilitates the proper membrane dynamics and cargo sorting necessary for the delivery of melanosomal proteins (e.g., TYR, TYRP1), the packaging of bioactive molecules into platelet dense granules, and the regulated secretion of cytolytic effectors in cytotoxic T lymphocytes. Disruption of HPS5 leads to impaired biogenesis and trafficking of these organelles, phenocopying features of Hermansky-Pudlak syndrome type 5.
In the NCI-H1975 lung adenocarcinoma background, knockout of HPS5 provides a unique platform to study the intersection between lysosome-related organelle biology and cancer cell homeostasis. Defective BLOC-2 function may alter lysosomal positioning, autophagy flux, and metabolic adaptability??processes frequently dysregulated in cancer. Given the association of abnormal lysosomal trafficking with drug sequestration and resistance, this model can be instrumental in exploring whether HPS5 loss influences sensitivity to EGFR TKIs or contributes to invasive and metastatic behaviors. Furthermore, it allows investigation of how melanosome-related pathways, typically restricted to melanocytes, may be aberrantly activated in tumor cells and impact tumor?Cstroma interactions.
Researchers can employ this polyclonal knockout model in a wide array of experimental applications. Western blotting and RT-qPCR confirm HPS5 ablation and assess downstream effectors. Immunofluorescence microscopy using antibodies against LAMP1, LAMP2, and melanosomal markers enables visualization of lysosome and lysosome-related organelle morphology. Functional assays such as cell proliferation, migration, and invasion provide insights into BLOC-2’s role in tumor aggressiveness. Flow cytometric analyses of cell cycle and apoptosis, combined with lysosomal function assays, help elucidate the impact on cellular fitness. Drug sensitivity profiling with EGFR TKIs can reveal potential therapeutic vulnerabilities. For additional information, please contact Ascent Research.
